Timothy M. Nywening

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

Yu Zhu, Brett L. Knolhoff, Melissa A. Meyer et al. · Cancer Research · 2014 · 1.3K citations · Full text

Medicine, Immunology, Oncology +17

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

Hong Jiang, Samarth Hegde, Brett L. Knolhoff et al. · Nature Medicine · 2016 · 1K citations · Full text

Medicine, Cancer Biology, Oncology +10

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

Timothy M. Nywening, Andrea Wang‐Gillam, Dominic E. Sanford et al. · The Lancet Oncology · 2016 · 778 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeting both tumour-associated CXCR2⁺ neutrophils and CCR2⁺ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Timothy M. Nywening, Brian A. Belt, Darren R. Cullinan et al. · Gut · 2017 · 481 citations · Full text

Medicine, Immunology, Oncology +17

Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer

Naim U. Rashid, Xianlu L. Peng, Chong Jin et al. · Clinical Cancer Research · 2019 · 238 citations · Full text

Medicine, Bioinformatics, Oncology +17